Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital Zhejiang UniversityActive in the last 2 years

Xiaozhen Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3567-8789; OpenAlex author ID A5101761128. Sources: OpenAlex.

Their work

Papers
17 (first author 8, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 6 papers · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 17

  1. Targeting SLC6A14-mediated nutrient competition reverses an immunosuppressive metabolic niche in pancreatic cancer. Co-author DOI 10.1186/s40164-026-00818-9↗
  2. Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial. Co-author DOI 10.1200/jco-26-01393↗
  3. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. First author DOI 10.1002/cac2.70038↗
  4. Lactate metabolism reprogramming in PDAC: Potential for tumor therapy. Co-author DOI 10.1016/j.bbcan.2025.189373↗
  5. Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer. First author DOI 10.1038/s41467-025-63146-2↗
  6. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Co-author DOI 10.1080/15548627.2023.2300913↗
  7. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. Co-author DOI 10.1002/jmv.28108↗
  8. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. First author DOI 10.1016/j.ymthe.2023.07.021↗
  9. Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix. First author DOI 10.1038/s41388-023-02711-9↗
  10. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. First author DOI 10.1038/s41418-022-01102-z↗
  11. Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Co-author DOI 10.2217/imt-2021-0075↗
  12. Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer. First author DOI 10.3390/cancers15082225↗
  13. Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. First author DOI 10.1038/s41388-021-01763-z↗
  14. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Co-author DOI 10.1038/s41467-021-24769-3↗
  15. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. Co-author DOI 10.1002/jmri.27024↗
  16. Eating self for not be eaten: Pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation. First author DOI 10.1038/s41392-020-0209-8↗
  17. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. Co-author DOI 10.1038/s41416-019-0595-2↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xueli Bai · 14 shared papers, 2019–2026 · strength 2.28
  2. Tingbo Liang · 14 shared papers, 2019–2026 · strength 2.22
  3. Lihong He · 8 shared papers, 2023–2026 · strength 1.52
  4. Mengyi Lao · 9 shared papers, 2020–2025 · strength 1.39
  5. Kang Sun · 7 shared papers, 2023–2025 · strength 1.36
  6. Hanshen Yang · 8 shared papers, 2021–2025 · strength 1.36
  7. Jian Xu · 6 shared papers, 2021–2024 · strength 0.94
  8. Lingyue Liu · 2 shared papers, 2025–2026 · strength 0.47
  9. Yi Duan · 3 shared papers, 2021–2023 · strength 0.44
  10. Tingbo Liang · 2 shared papers, 2025–2026 · strength 0.44
  11. Yan Chen · 2 shared papers, 2023–2025 · strength 0.34
  12. Enliang Li · 2 shared papers, 2021–2023 · strength 0.34
  13. Xueli Bai · 1 shared paper, 2025 · strength 0.33
  14. Fan Gao · 1 shared paper, 2025 · strength 0.33
  15. Risheng Que · 2 shared papers, 2020–2026 · strength 0.31
  16. Qi Chen · 2 shared papers, 2019–2023 · strength 0.30
  17. Xing Huang · 2 shared papers, 2020–2021 · strength 0.28
  18. Yinan Shen · 2 shared papers, 2020–2023 · strength 0.23
  19. Daqian Xu · 1 shared paper, 2025 · strength 0.22
  20. Guoliang Qiao · 1 shared paper, 2026 · strength 0.22
  21. Tianan Jiang · 1 shared paper, 2026 · strength 0.22
  22. Tianyu Tang · 2 shared papers, 2020–2021 · strength 0.21
  23. Junming Huang · 1 shared paper, 2025 · strength 0.19
  24. Xiongbin Lu · 1 shared paper, 2025 · strength 0.19
  25. Xinyuan Liu · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.